外用咪喹莫特治疗基底细胞癌、光化性角化病和其他皮肤病变的综述

Jubin Ryu, F. C. Yang
{"title":"外用咪喹莫特治疗基底细胞癌、光化性角化病和其他皮肤病变的综述","authors":"Jubin Ryu, F. C. Yang","doi":"10.4137/CMT.S1969","DOIUrl":null,"url":null,"abstract":"Imiquimod (trade name Aldara™) is a small molecule of the imidazoquinoline family, a group of nucleoside analogs that were first synthesized as potential antiviral agents. It has since been discovered to activate both innate and adaptive immunity, as well as apoptosis. Clinically, it has been approved for three indications thus far: external genital warts, actinic keratosis, and superficial basal cell carcinoma. In addition to these applications, a number of off-label uses have been reported in the literature. In this review, we summarize and discuss the literature describing imiquimod’s mechanism of action, its approved and off-label clinical uses, and its safety and tolerability.","PeriodicalId":10428,"journal":{"name":"Clinical Medicine and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions\",\"authors\":\"Jubin Ryu, F. C. Yang\",\"doi\":\"10.4137/CMT.S1969\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Imiquimod (trade name Aldara™) is a small molecule of the imidazoquinoline family, a group of nucleoside analogs that were first synthesized as potential antiviral agents. It has since been discovered to activate both innate and adaptive immunity, as well as apoptosis. Clinically, it has been approved for three indications thus far: external genital warts, actinic keratosis, and superficial basal cell carcinoma. In addition to these applications, a number of off-label uses have been reported in the literature. In this review, we summarize and discuss the literature describing imiquimod’s mechanism of action, its approved and off-label clinical uses, and its safety and tolerability.\",\"PeriodicalId\":10428,\"journal\":{\"name\":\"Clinical Medicine and Therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine and Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/CMT.S1969\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/CMT.S1969","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

摘要

咪喹莫特(商品名Aldara™)是咪唑喹啉家族的一种小分子,是一组核苷类似物,最初被合成为潜在的抗病毒药物。它已经被发现可以激活先天免疫和适应性免疫,以及细胞凋亡。在临床上,它已被批准用于三种适应症:外生殖器疣、光化性角化病和浅表基底细胞癌。除了这些应用之外,文献中还报道了一些标签外的用途。在这篇综述中,我们总结和讨论了描述咪喹莫特的作用机制,其批准和超说明书临床应用,以及其安全性和耐受性的文献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions
Imiquimod (trade name Aldara™) is a small molecule of the imidazoquinoline family, a group of nucleoside analogs that were first synthesized as potential antiviral agents. It has since been discovered to activate both innate and adaptive immunity, as well as apoptosis. Clinically, it has been approved for three indications thus far: external genital warts, actinic keratosis, and superficial basal cell carcinoma. In addition to these applications, a number of off-label uses have been reported in the literature. In this review, we summarize and discuss the literature describing imiquimod’s mechanism of action, its approved and off-label clinical uses, and its safety and tolerability.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信